Cargando…

Elevated plasma levels of IL-6 and MCP-1 selectively identify CML patients who better sustain molecular remission after TKI withdrawal

Treatment-free remission (TFR) in chronic myeloid leukemia (CML) is safe under adequate molecular monitoring, but questions remain regarding which factors may be considered predictive for TFR. Argentina Stop Trial (AST) is a multicenter TFR trial showing that 65% of patients sustain molecular remiss...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pavlovsky, Carolina, Vasconcelos Cordoba, Bianca, Sanchez, María Belén, Moiraghi, Beatriz, Varela, Ana, Custidiano, Rosario, Fernandez, Isolda, Freitas, Maria Josefina, Ventriglia, Maria Verónica, Bendek, Georgina, Mariano, Romina, Mela Osorio, María José, Pavlovsky, Miguel Angel, de Labanca, Ana García, Foncuberta, Cecilia, Giere, Isabel, Vera, Masiel, Juni, Mariana, Mordoh, Jose, Sanchez Avalos, Julio Cesar, Cueto, Gerardo, Miranda, Silvia, Levy, Estrella Mariel, Bianchini, Michele
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10148988/ https://www.ncbi.nlm.nih.gov/pubmed/37120577 http://dx.doi.org/10.1186/s13045-023-01440-6

Ejemplares similares

In-depth characterization of NK cell markers from CML patients who discontinued tyrosine kinase inhibitor therapy
por: Sanchez, María Belén, et al.
Publicado: (2023)

Evaluation of the primitive fraction by functional in vitro assays at the RNA and DNA level represents a novel tool for complementing molecular monitoring in chronic myeloid leukemia
por: Ruiz, María Sol, et al.
Publicado: (2018)

miRNome profiling of LSC-enriched CD34(+)CD38(−)CD26(+) fraction in Ph(+) CML-CP samples from Argentinean patients: a potential new pharmacogenomic tool
por: Ruiz, María Sol, et al.
Publicado: (2021)

Planned Pregnancy in a Chronic Myeloid Leukemia Patient in Molecular Remission
por: Pavlovsky, Carolina, et al.
Publicado: (2012)

Growth effect of tki treatment in childhood CML
por: Jeon, Yeon Jin, et al.
Publicado: (2015)

Is There a Role for Dose Modification of TKI Therapy in CML?
por: Copland, M.
Publicado: (2019)

Drug Therapy in the Progressed CML Patient with multi-TKI Failure
por: Haznedaroglu, Ibrahim C.
Publicado: (2015)

Aplasia in Chronic Phase CML Post-TKI Therapy: A Management Dilemma
por: Ramdial, Jeremy L., et al.
Publicado: (2019)

Combination of PKCδ Inhibition with Conventional TKI Treatment to Target CML Models
por: Muselli, Fabien, et al.
Publicado: (2021)

Blast Crisis of CML After TKI Discontinuation in a Patient With Previous Stable Deep Molecular Response: Is It Safe to Stop?
por: Papalexandri, Apostolia, et al.
Publicado: (2018)

The occurrence and management of fluid retention associated with TKI therapy in CML, with a focus on dasatinib
por: Masiello, David, et al.
Publicado: (2009)

Monitoring the Response to Tyrosine Kinase Inhibitor (TKI) Treatment in Chronic Myeloid Leukemia (CML)
por: Haznedaroglu, Ibrahim C.
Publicado: (2014)

Monitoring of immunity against leukemia stem cell in CML patients after cessation of TKI
por: Matsushita, Maiko, et al.
Publicado: (2015)

Variable Behavior of iPSCs Derived from CML Patients for Response to TKI and Hematopoietic Differentiation
por: Bedel, Aurélie, et al.
Publicado: (2013)

Delayed Diagnosis and Multi-TKI Intolerance: A Case Report of CML Concurrent With COVID-19
por: Luan, Chengxin, et al.
Publicado: (2022)

Psychological Factors Affecting the Willingness to Accept a Possible Tyrosine Kinase Inhibitor (TKI) Discontinuation in Chronic Myeloid Leukaemia (CML) Patients
por: Cutica, Ilaria, et al.
Publicado: (2022)

Re-balance of memory T cell subsets in peripheral blood from patients with CML after TKI treatment
por: Yao, Danlin, et al.
Publicado: (2017)

Excellent outcomes of 2G-TKI therapy after imatinib failure in chronic phase CML patients
por: Tiribelli, Mario, et al.
Publicado: (2018)

TKI rotation-induced persistent deep molecular response in multi-resistant blast crisis of Ph+ CML
por: Valent, Peter, et al.
Publicado: (2017)

Evaluation of CML TKI Induced Cardiovascular Toxicity and Development of Potential Rescue Strategies in a Zebrafish Model
por: Cheng, Shan, et al.
Publicado: (2021)

Natural Killer Cells in Human Cancer: From Biological Functions to Clinical Applications
por: Levy, Estrella Mariel, et al.
Publicado: (2011)

Biological role of NK cells and immunotherapeutic approaches in breast cancer
por: Roberti, María P., et al.
Publicado: (2012)

Editorial: “Cancer Immunotherapy: Lights and Shadows”
por: Barrio, María Marcela, et al.
Publicado: (2015)

Treatment-free remission in patients with chronic myeloid leukemia: recommendations of the LALNET expert panel
por: Pavlovsky, Carolina, et al.
Publicado: (2021)

Knockout of LASP1 in CXCR4 expressing CML cells promotes cell persistence, proliferation and TKI resistance
por: Herrmann, Andreas B., et al.
Publicado: (2020)

P669: ANALYSIS OF FACTORS INFLUENCING THE DECISION TO STOP TKI TREATMENT IN CML PATIENTS IN DEEP MOLECULAR RESPONSE
por: Semerad, Lukas, et al.
Publicado: (2023)

Potestad /
por: Pavlovsky, Eduardo A.
Publicado: (1987)

La ética del cuerpo : nuevas conversaciones con Jorge Dubatti /
por: Pavlovsky, Eduardo A.
Publicado: (2001)

Teatro completo /
por: Pavlovsky, Eduardo A.
Publicado: (1997)

El señor Galindez y Pablo
por: Pavlovsky, Eduardo A.
Publicado: (1986)

P041: Low percentage of T lymphocytes in Hodgkin’s Lymphoma lymph nodes, measured by flow cytometry, is associated with inferior progression free survival regardless of negative interim pet scan status
por: Korin, Laura, et al.
Publicado: (2022)

CDKIs p18(INK4c) and p57(Kip2) are involved in quiescence of CML leukemic stem cells after treatment with TKI
por: Moreno-Lorenzana, Dafne, et al.
Publicado: (2016)

Selective JAK2/ABL dual inhibition therapy effectively eliminates TKI-insensitive CML stem/progenitor cells
por: Lin, Hanyang, et al.
Publicado: (2014)

Quantitative prediction of long-term molecular response in TKI-treated CML – Lessons from an imatinib versus dasatinib comparison
por: Glauche, Ingmar, et al.
Publicado: (2018)

Exome, transcriptome and miRNA analysis don’t reveal any molecular markers of TKI efficacy in primary CML patients
por: Lavrov, Alexander V., et al.
Publicado: (2019)

PVR and ICAM-1 on Blast Crisis CML Stem and Progenitor Cells with TKI Resistance Confer Susceptibility to NK Cells
por: Kim, Nayoung, et al.
Publicado: (2020)

Successful treatment discontinuation in CML patients with full-dose and low-dose TKI: Results from real-world practice
por: Chen, Yilin, et al.
Publicado: (2023)

Feasibility of the imatinib stop study in the Japanese clinical setting: delightedly overcome CML expert stop TKI trial (DOMEST Trial)
por: Fujisawa, Shin, et al.
Publicado: (2018)

Venetoclax resistance induced by activated T cells can be counteracted by sphingosine kinase inhibitors in chronic lymphocytic leukemia
por: Sarapura Martinez, Valeria J., et al.
Publicado: (2023)

Analytical Solutions for Simple Turbulent Shear Flows on a Basis of a Generalized Newton’s Law
por: Nikushchenko, Dmitry, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_c74dp479aa30njimep3ubbbble